Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Feb;19(2):417-428.
doi: 10.1111/jth.15157. Epub 2020 Nov 21.

A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity

Emmanuel J Favaloro  1   2   3 , Soma Mohammed  1   2 , Kent Chapman  2   4 , Priscilla Swanepoel  2   4 , Diane Zebeljan  2   5 , Opelo Sefhore  2   5 , Erica Malan  6 , Joanne Clifford  6 , Agnes Yuen  6 , Dea Donikian  2   7 , Mayuko Kondo  2   7 , Elizabeth Duncan  8 , Sunil Abraham  8 , Joanne Beggs  9 , Ritesh Chatrapati  9 , Joanne Perel  9 , Robyn Coleman  10 , Nathan Klose  10 , Danny Hsu  2   5 , Penelope Motum  2   5 , Chee Wee Tan  8   11 , Timothy Brighton  2   7 , Leonardo Pasalic  1   2   3
Affiliations
Free article
Multicenter Study

A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity

Emmanuel J Favaloro et al. J Thromb Haemost. 2021 Feb.
Free article

Abstract

Background: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially fatal disorder caused by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) deficiency. Prompt identification/exclusion of TTP can thus be facilitated by rapid ADAMTS13 testing. The most commonly utilized (enzyme-linked immunosorbent assay [ELISA]-based) assay takes several hours to perform and so does not generally permit rapid testing.

Objectives: To evaluate the utility of a new automated test for ADAMTS13 activity, the HemosIL AcuStar ADAMTS13 Activity assay, based on chemiluminescence and able to be performed on an ACL AcuStar instrument within 33 minutes.

Patients/methods: This multicenter (n = 8) assessment included testing of more than 700 test samples, with similar numbers of prospective (n = 348) and retrospective (n = 385) samples. The main comparator was the Technozym ADAMTS13 Activity ELISA. We also assessed comparative performance for detection of ADAMTS13 inhibitors using a Bethesda assay.

Results: Overall, the chemiluminescent assay yielded similar results to the comparator ELISA, albeit with slight negative bias. ADAMTS13 inhibitor detection was also comparable, albeit with slight positive bias with the AcuStar assay. Assay precision was similar with both assays, and we also verified assay normal reference ranges.

Conclusions: The HemosIL AcuStar ADAMTS13 Activity assay provided results rapidly, which were largely comparable with the Technozym ADAMTS13 Activity ELISA assay, albeit lower on average. Conversely, inhibitor levels tended to be identified at a higher level on average. Thus, the HemosIL AcuStar ADAMTS13 Activity assay provides a fast and accurate means to quantitate plasma levels of ADAMTS13 for TTP/ADAMTS13 identification/exclusion, and potentially also for other applications.

Keywords: ADAMTS13 activity; ADAMTS13 inhibitors; TTP; laboratory testing; thrombotic thrombocytopenic purpura.

PubMed Disclaimer

References

REFERENCES

    1. Singer K, Bornstein F, Wiles A. Thrombotic thrombocytopenia purpura. Blood. 1947;2:542-544.
    1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc. 1924;24:21-24.
    1. Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost. 2020;46(3):289-301.
    1. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombycytopenic purpura. N Engl J Med. 1982;307(23):1432-1435.
    1. Furlan M, Robels R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87(10):4223-4234.

Publication types

LinkOut - more resources